Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.

Expert opinion on drug metabolism & toxicology - 1 Dec 2023

Tuan Jessica, Okoli Adaora, Ogbuagu Onyema

Abstract excerpt

INTRODUCTION: The World Health Organization proposed targets to eliminate hepatitis C virus (HCV) by 2030, aiming to treat ≥80% of people with HCV, decreasing new chronic infections by 90% and liver-related mortality by 65%. While children/adolescents represent a minority of cases, the true burden is underestimated. Advances in drug development have resulted in simplified treatments that are well-tolerated,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzopyrans

Share to Carbamates

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Heterocyclic Compounds, 4 or More Rings

Share to Sofosbuvir

Source

Identifiers

PMID: 38058292
DOI: 10.1080/17425255.2023.2292736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.PMID 38058292Read ↗

Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.Semantic proximity Read ↗

Treatment of hepatitis C in children and adolescents: how far have we reached?Semantic proximity Read ↗

[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].Semantic proximity Read ↗

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.Semantic proximity Read ↗

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.Semantic proximity Read ↗

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings.Semantic proximity Read ↗

[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].Semantic proximity Read ↗

Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.Semantic proximity Read ↗

Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children.Semantic proximity Read ↗

Hepatitis C virus in infants and children.Semantic proximity Read ↗

Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infectionSemantic proximity Read ↗

Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.